A composition for use in the treatment of fistula, the composition comprising activated carbon.

A composition for use in the treatment of fistula, the composition comprising activated carbon.

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.

A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.

An object of the present invention is to provide an adsorbent for oral administration capable of adsorbing large quantities of indole in the presence of bile acid.

The above problem can be solved by an adsorbent for oral administration comprising a spherical activated carbon, the activated carbon having a specific surface area determined by the BET method of 800 m.sup.2/g or more, a bulk density of from 0.3 g/mL to 0.8 g/mL, a volume of pores having a diameter less than 3 nm of 0.3 mL/g or more, and a micropore/mesopore ratio (Vm) determined by Formula (1): Vm=Vmic/Vmet (1) wherein Vmic is a volume of pores having a diameter less than 3 nm, and Vmet is a volume of pores having a diameter from 3 nm to 50 nm; of 3.0 or more.

An object of the present invention is to provide an adsorbent for oral administration capable of adsorbing large quantities of indole in the presence of bile acid.

The above problem can be solved by an adsorbent for oral administration comprising a spherical activated carbon, the activated carbon having a specific surface area determined by the BET method of 800 m.sup.2/g or more, a bulk density of from 0.3 g/mL to 0.8 g/mL, a volume of pores having a diameter less than 3 nm of 0.3 mL/g or more, and a micropore/mesopore ratio (Vm) determined by Formula (1): Vm=Vmic/Vmet (1) wherein Vmic is a volume of pores having a diameter less than 3 nm, and Vmet is a volume of pores having a diameter from 3 nm to 50 nm; of 3.0 or more.

Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.

Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.

Provided herein are compositions, including products of manufacture such as formulations, and kits, and methods, for treatment, amelioration or prevention of a disease, infection or condition caused or exacerbated by a pathological or abnormal in situ microbiome space, or a gastrointestinal (GI), disease, infection or condition or a disease or condition caused by, initiated by or exacerbated by a pathological microbiome, e.g., by a pathological GI or colonic microbiome residing in a gut mucosa.

The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon.